Company news

Share this article:
Eli Lilly announced a definitive agreement to acquire SGX Pharmaceuticals, a biotech specializing in oncology products, for $64 million, in an all-cash transaction.

Sudler & Hennessey announced the launch of 98.6°, a new patient health division. Jeanne Cloppse, managing director, will oversee the team. Areas of focus include disease state communications, treatment option and decisions, healthcare systems and the importance of compliance.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.